Hodgkin lymphoma: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

• All targets
• CD20 2
• CD19 10
• PD-1 9
• CD30 9
• PD-L1 2
• BCL-2 2
• STAT3 0
• CD47 1
• JAK 1
• MYC 2
• TP53 0
• ALK 0
• BTK 1
• CD22 0
• IL-6 0
• AKT 0
• CTLA-4 0
• mTOR 0
• PI3K 0
• PRMT5 1
• ABL1 0
• BCMA 0
• CD123 1
• CD38 0
• EZH2 0
• METTL3 0
• NOTCH1 0
• NRF2 0
• TIM-3 0
• AMPK 0
• AXL 0
• BDNF 1
• CCR5 0
• CDK4/6 0
• CXCR4 0
• FGFR 0
• FLT3 0
• GLP-1 0
• HDAC 0
• IL-15 1
• IL-17 0
• MET 0
• MMP-9 0
• NLRP3 0
• PARP 0
• PRAME 0
• SGLT2 0
• SIRT1 0
• TERT 0
• TIGIT 0
• TLR4 0
• TNF 0

EU-13 is a filter, not a ranking: it only narrows the list.

24 of 37+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  Study to Evaluate the Safety and Efficacy of a Combination of Favezelimab (MK-4280) and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies (MK-4280-003)

  NCT03598608· Merck Sharp & Dohme LLC· Updated 28 Jul 2026

  “Business Reason”Registry text, quoted unchanged. Source

• Withdrawn

  Anti-PD-1 Antibody Treatment With Cemiplimab and Radiotherapy in Early-stage Classical Hodgkin Lymphoma

  NCT04373083· Regeneron Pharmaceuticals· Updated 15 Jan 2021

  “Business Decision”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667)

  NCT03407144· Merck Sharp & Dohme LLC· Source

• A Study of Pembrolizumab (MK-3475) in Relapsed or Refractory Classical Hodgkin's Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) (MK-3475-B68)

  NCT04875195· Merck Sharp & Dohme LLC· Source

• A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (MK-4280A-008)

  NCT05508867· Merck Sharp & Dohme LLC· Source

• Study to Evaluate the Safety and Efficacy of a Combination of Favezelimab (MK-4280) and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies (MK-4280-003)

  NCT03598608· Merck Sharp & Dohme LLC· Source

• A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)

  NCT02332668· Merck Sharp & Dohme LLC· Source

• Study of Pembrolizumab (MK-3475) vs. Brentuximab Vedotin in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-204/KEYNOTE-204)

  NCT02684292· Merck Sharp & Dohme LLC· Source

• A Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) Coformulated With Berahyaluronidase Alfa (MK-3475A) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL)(MK-3475A-F65)

  NCT06504394· Merck Sharp & Dohme LLC· Source

• Safety and Preliminary Efficacy Assessment of AZD7789 in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

  NCT05216835· AstraZeneca· Source

• Study of Safety and Efficacy of Pembrolizumab and Chemotherapy in Participants With Newly Diagnosed Classical Hodgkin Lymphoma (cHL) (MK-3475-C11/KEYNOTE-C11)

  NCT05008224· Merck Sharp & Dohme LLC· Source

• Treatment Strategy for Relapsed/Refractory Hodgkin Lymphoma

  NCT05595447· Hospital Regional de Alta Especialidad del Bajio· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 5
• Mendelian Randomization Analysis 6
• CRISPR-Cas Systems 1
• Gene Expression Profiling 14
• Whole Genome Sequencing 1
• Exome Sequencing 3
• Proteomics 5
• Metabolomics 1
• Flow Cytometry 9
• Immunohistochemistry 19
• Liquid Biopsy 1
• Circulating Tumor DNA 6
• Xenograft Model Antitumor Assays 20
• Positron-Emission Tomography 21
• Magnetic Resonance Imaging 18
• Machine Learning 11
• Deep Learning 3
• Cohort Studies 30
• Genome-Wide Association Study 7

• CytoVI: deep generative modeling of antibody-based single cell data.

  Nat Methods, Sept 2026

• Self-explaining artificial intelligence for the classification of B cell non-Hodgkin lymphoma: A diagnostic decision support study.

  PLoS Med, Jul 2026

• Peripheral blood immune profiling reveals key signatures in newly diagnosed NK/T cell lymphoma patients.

  Theranostics, Jun 2026

• Integrating Flow Cytometry in the Diagnostic Work of HIV-Associated Hodgkin's Lymphomas.

  J Cell Mol Med, May 2026

• Generation of a Rabbit Anti-Canine CD19 Monoclonal Antibody From Peripheral Blood and Its Validation in Immunoassays and CAR-T Feasibility.

  Vet Comp Oncol, Mar 2026

• Flow Cytometry as an Adjunct to Fine Needle Aspiration Cytology in the Diagnosis and Subtyping of Non-Hodgkin Lymphoma.

  Cytopathology, Dec 2025

• Comprehensive Cytopathologic, Flow Cytometric and Immunocytochemical Analysis of a Challenging Case of Small Cell Variant of Anaplastic Large T-Cell Lymphoma in a Child.

  Cytopathology, Dec 2025

• Evaluation of CD20-Positive B Cells in Libyan Lymphoma Patients Following Rituximab Treatment.

  Asian Pac J Cancer Prev, Nov 2025

• Ascorbate promotes epigenetic activation of CD30 in human embryonic stem cells.

  Stem Cells, Oct 2010

See which targets of this disease your abstract mentions, and go to the people working on them.